Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)
Prospectively Validating the 4Ts and Chong Score for Heparin Induced Thrombocytopenia
Sponsor: GlaxoSmithKline
Listed as NCT00946400, this observational or N/A phase trial focuses on Heparin-Induced Thrombocytopenia and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 11 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Sep 2020 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Sep 2020 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Medstar Health Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .